TL;DR
Although obese individuals showed quantitatively higher CAP and liver stiffness values, non-obese individuals with T2D also exhibited clinically meaningful hepatic steatosis and fibrosis.
Abdominal adiposity identifies steatosis risk in a graded manner but does not discriminate fibrosis, supporting adiposity- and sex-informed hepatic phenotyping in patients with T2DM.
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM). Non-invasive tools (NITs) such as the FIB-4 index, are widely used for risk stratification to identify patients at higher risk of progressive liver disease. This study aim...
Patients with T2DM, cardiovascular disease, and blood-based indices suggesting liver steatosis or fibrosis differed significantly with respect to the lipid profile, and an elevated HSI score, suggesting steatosis, was associated with dyslipidemia, and an elevated NFS score, suggesting fibrosis, was not.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among individuals with severe obesity. The triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) is an accessible surrogate marker of insulin resistance, but its association with hepatic steatosis and fibrosis in candid...
Microalbuminuria was strongly associated with greater hepatic steatosis, higher liver stiffness, increased fibrosis burden, endothelial dysfunction, and systemic inflammation in patients with MASLD and support further prospective investigation of microalbuminuria and endothelial biomarkers as noninvasive tools for fibr...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
